Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
AMLOX-NH trial of amlodipine versus hydrochlorothiazide on oxidative stress in adult Nigerian patients with hypertension
PACTR202407549032623Phase 2Not yet recruiting
- Sponsor
- Ejiroghene Umuerri
- Start
- Aug 2024
- Modality
- Small Molecules
- Countries
- 1
01
Overview
Phase 2, randomised trial of amlodipine and hydrochlorothiazide in hypertension (HTN), sponsored by Ejiroghene Umuerri. Primary endpoints: Mean change in malondialdehyde and Mean change in superoxide dismutase. Planned start Aug 2024; status: not yet recruiting.
02
Drugs
amlodipinehydrochlorothiazide
03
Conditions
hypertension (HTN)
Beyond the preview
Go deeper on PACTR202407549032623.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on PACTR202407549032623.